Cargando…

2039: Modifiable risk factors Versus age on developing high predicted cardiovascular disease risk in African Americans

OBJECTIVES/SPECIFIC AIMS: Clinical guidelines recommend using predicted atherosclerotic cardiovascular disease (ASCVD) risk to inform treatment decisions. The objective was to compare the contribution of changes in modifiable risk factors Versus aging to the development of high 10-year predicted ASC...

Descripción completa

Detalles Bibliográficos
Autores principales: Bress, Adam, Colantonio, Lisandro D., Booth, John N., Spruill, Tanya M., Ravenell, Joseph, Butler, Mark, Shallcross, Amanda J., Seals, Samantha R., Reynolds, Kristi, Ogedegbe, Gbenga, Shimbo, Daichi, Muntner, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6798451/
http://dx.doi.org/10.1017/cts.2017.90
_version_ 1783460048795598848
author Bress, Adam
Colantonio, Lisandro D.
Booth, John N.
Spruill, Tanya M.
Ravenell, Joseph
Butler, Mark
Shallcross, Amanda J.
Seals, Samantha R.
Reynolds, Kristi
Ogedegbe, Gbenga
Shimbo, Daichi
Muntner, Paul
author_facet Bress, Adam
Colantonio, Lisandro D.
Booth, John N.
Spruill, Tanya M.
Ravenell, Joseph
Butler, Mark
Shallcross, Amanda J.
Seals, Samantha R.
Reynolds, Kristi
Ogedegbe, Gbenga
Shimbo, Daichi
Muntner, Paul
author_sort Bress, Adam
collection PubMed
description OBJECTIVES/SPECIFIC AIMS: Clinical guidelines recommend using predicted atherosclerotic cardiovascular disease (ASCVD) risk to inform treatment decisions. The objective was to compare the contribution of changes in modifiable risk factors Versus aging to the development of high 10-year predicted ASCVD risk. METHODS/STUDY POPULATION: Prospective follow-up of the Jackson Heart Study, an exclusively African-American cohort, at visit 1 (2000–2004) and visit 3 (2009–2012). Analyses included 1115 African-American participants without a high 10-year predicted ASCVD risk (<7.5%), hypertension, diabetes, or ASCVD at visit 1. We used the Pooled Cohort equations to calculate the incidence of high (≥7.5%) 10-year predicted ASCVD risk at visit 3. We recalculated the percentage with a high 10-year predicted ASCVD risk at visit 3 assuming each risk factor [age, systolic blood pressure (SBP), antihypertensive medication use, diabetes, smoking, total and high-density lipoprotein cholesterol], one at a time, did not change from visit 1. RESULTS/ANTICIPATED RESULTS: The mean age at visit 1 was 45.2±9.5 years. Overall, 30.9% (95% CI 28.3%–33.4%) of participants developed high 10-year predicted ASCVD risk. Aging accounted for 59.7% (95% CI 54.2%–65.1%) of the development of high 10-year predicted ASCVD risk compared with 32.8% (95% CI 27.0%–38.2%) for increases in SBP or antihypertensive medication initiation and 12.8% (95% CI 9.6%–16.5%) for incident diabetes. Among participants <50 years, the contribution of increases in SBP or antihypertensive medication initiation was similar to aging. DISCUSSION/SIGNIFICANCE OF IMPACT: Increases in SBP and antihypertensive medication initiation are major contributors to the development of high 10-year predicted ASCVD risk in African Americans, particularly among younger adults.
format Online
Article
Text
id pubmed-6798451
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-67984512019-10-28 2039: Modifiable risk factors Versus age on developing high predicted cardiovascular disease risk in African Americans Bress, Adam Colantonio, Lisandro D. Booth, John N. Spruill, Tanya M. Ravenell, Joseph Butler, Mark Shallcross, Amanda J. Seals, Samantha R. Reynolds, Kristi Ogedegbe, Gbenga Shimbo, Daichi Muntner, Paul J Clin Transl Sci Clinical Epidemiology OBJECTIVES/SPECIFIC AIMS: Clinical guidelines recommend using predicted atherosclerotic cardiovascular disease (ASCVD) risk to inform treatment decisions. The objective was to compare the contribution of changes in modifiable risk factors Versus aging to the development of high 10-year predicted ASCVD risk. METHODS/STUDY POPULATION: Prospective follow-up of the Jackson Heart Study, an exclusively African-American cohort, at visit 1 (2000–2004) and visit 3 (2009–2012). Analyses included 1115 African-American participants without a high 10-year predicted ASCVD risk (<7.5%), hypertension, diabetes, or ASCVD at visit 1. We used the Pooled Cohort equations to calculate the incidence of high (≥7.5%) 10-year predicted ASCVD risk at visit 3. We recalculated the percentage with a high 10-year predicted ASCVD risk at visit 3 assuming each risk factor [age, systolic blood pressure (SBP), antihypertensive medication use, diabetes, smoking, total and high-density lipoprotein cholesterol], one at a time, did not change from visit 1. RESULTS/ANTICIPATED RESULTS: The mean age at visit 1 was 45.2±9.5 years. Overall, 30.9% (95% CI 28.3%–33.4%) of participants developed high 10-year predicted ASCVD risk. Aging accounted for 59.7% (95% CI 54.2%–65.1%) of the development of high 10-year predicted ASCVD risk compared with 32.8% (95% CI 27.0%–38.2%) for increases in SBP or antihypertensive medication initiation and 12.8% (95% CI 9.6%–16.5%) for incident diabetes. Among participants <50 years, the contribution of increases in SBP or antihypertensive medication initiation was similar to aging. DISCUSSION/SIGNIFICANCE OF IMPACT: Increases in SBP and antihypertensive medication initiation are major contributors to the development of high 10-year predicted ASCVD risk in African Americans, particularly among younger adults. Cambridge University Press 2018-05-10 /pmc/articles/PMC6798451/ http://dx.doi.org/10.1017/cts.2017.90 Text en © The Association for Clinical and Translational Science 2018 http://creativecommons.org/licenses/by/4.0/ This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Epidemiology
Bress, Adam
Colantonio, Lisandro D.
Booth, John N.
Spruill, Tanya M.
Ravenell, Joseph
Butler, Mark
Shallcross, Amanda J.
Seals, Samantha R.
Reynolds, Kristi
Ogedegbe, Gbenga
Shimbo, Daichi
Muntner, Paul
2039: Modifiable risk factors Versus age on developing high predicted cardiovascular disease risk in African Americans
title 2039: Modifiable risk factors Versus age on developing high predicted cardiovascular disease risk in African Americans
title_full 2039: Modifiable risk factors Versus age on developing high predicted cardiovascular disease risk in African Americans
title_fullStr 2039: Modifiable risk factors Versus age on developing high predicted cardiovascular disease risk in African Americans
title_full_unstemmed 2039: Modifiable risk factors Versus age on developing high predicted cardiovascular disease risk in African Americans
title_short 2039: Modifiable risk factors Versus age on developing high predicted cardiovascular disease risk in African Americans
title_sort 2039: modifiable risk factors versus age on developing high predicted cardiovascular disease risk in african americans
topic Clinical Epidemiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6798451/
http://dx.doi.org/10.1017/cts.2017.90
work_keys_str_mv AT bressadam 2039modifiableriskfactorsversusageondevelopinghighpredictedcardiovasculardiseaseriskinafricanamericans
AT colantoniolisandrod 2039modifiableriskfactorsversusageondevelopinghighpredictedcardiovasculardiseaseriskinafricanamericans
AT boothjohnn 2039modifiableriskfactorsversusageondevelopinghighpredictedcardiovasculardiseaseriskinafricanamericans
AT spruilltanyam 2039modifiableriskfactorsversusageondevelopinghighpredictedcardiovasculardiseaseriskinafricanamericans
AT ravenelljoseph 2039modifiableriskfactorsversusageondevelopinghighpredictedcardiovasculardiseaseriskinafricanamericans
AT butlermark 2039modifiableriskfactorsversusageondevelopinghighpredictedcardiovasculardiseaseriskinafricanamericans
AT shallcrossamandaj 2039modifiableriskfactorsversusageondevelopinghighpredictedcardiovasculardiseaseriskinafricanamericans
AT sealssamanthar 2039modifiableriskfactorsversusageondevelopinghighpredictedcardiovasculardiseaseriskinafricanamericans
AT reynoldskristi 2039modifiableriskfactorsversusageondevelopinghighpredictedcardiovasculardiseaseriskinafricanamericans
AT ogedegbegbenga 2039modifiableriskfactorsversusageondevelopinghighpredictedcardiovasculardiseaseriskinafricanamericans
AT shimbodaichi 2039modifiableriskfactorsversusageondevelopinghighpredictedcardiovasculardiseaseriskinafricanamericans
AT muntnerpaul 2039modifiableriskfactorsversusageondevelopinghighpredictedcardiovasculardiseaseriskinafricanamericans